The HARMONi-2 trial showed that ivonescimab improved progression-free survival compared to pembrolizumab in PD-L1-positive advanced NSCLC. This first phase 3 study with ivonescimab highlights its potential as a new standard of care. The trial involved 398 patients and found that ivonescimab doubled PFS to 11.1 months. Ivonescimab also had higher response rates and a manageable safety profile, despite more adverse events. Further studies are needed, but Summit Therapeutics plans to initiate HARMONi-7 comparing ivonescimab to pembrolizumab in high PD-L1 expression NSCLC. The results suggest ivonescimab may offer a significant benefit in PD-L1-positive advanced NSCLC.
Source link
Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC
